Evotec SE (NASDAQ:EVO) Short Interest Up 89.9% in January

Evotec SE (NASDAQ:EVO) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 766,200 shares, an increase of 89.9% from the December 31st total of 403,500 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 232,100 shares, the days-to-cover ratio is presently 3.3 days.

Evotec Stock Performance

EVO stock traded up $0.02 during midday trading on Wednesday, reaching $4.22. 20,658 shares of the company’s stock traded hands, compared to its average volume of 52,542. The company has a 50-day simple moving average of $4.48 and a two-hundred day simple moving average of $4.05. Evotec has a 1-year low of $2.85 and a 1-year high of $7.98. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.

Institutional Investors Weigh In On Evotec

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Evotec during the second quarter worth $87,000. Clear Harbor Asset Management LLC bought a new position in Evotec during the third quarter worth about $104,000. Mediolanum International Funds Ltd bought a new position in Evotec during the third quarter worth about $512,000. Finally, Wellington Management Group LLP lifted its holdings in Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock worth $9,616,000 after acquiring an additional 602,858 shares in the last quarter. 5.81% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Evotec in a report on Thursday, November 7th. Jefferies Financial Group lowered Evotec from a “buy” rating to a “hold” rating and lowered their price objective for the company from $8.70 to $3.80 in a report on Monday, October 7th.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.